EUVIMEDEUVIMED entdecken
Crossref

A Critical Analysis of the FDA’s 2021 Mifepristone REMS Modification Rationale Review

Zachary Sluzala, Ingrid Skop

Issues in Law & Medicine · 2026

DOI: 10.70257/wfev6833 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Issues in Law & Medicine, 2026. Verfasst von Zachary Sluzala und 1 weiteren Autor:innen. Die Arbeit nennt 48 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mifepristone was first approved in 2000 in conjunction with misoprostol to induce abortion, and both its initial approval and subsequent regulation have been controversial. In 2021, the Food and Drug Administration (FDA) undertook a full review of the mifepristone Risk Evaluation and Mitigation Strategy (REMS) program, with the aim of assessing the necessity of each of the three Elements to Assure Safe Use (ETASUs) present in the mifepristone REMS, including ETASU C, the “in-person dispensing requirement.” Following this review, the FDA concluded that ETASU C could be safely removed and that mifepristone could be safely dispensed outside of the previously approved settings. This paper seeks to critically analyze the 2021 REMS Review, as well as the studies cited therein to determine whether the evidence presented by the FDA sufficiently substantiated this decision. Factors that render the cited studies non-replicative of real-world, non-study conditions and therefore unable to be generalized to these contexts are highlighted. Differential treatment of stakeholder input and limitations of abortion complication reporting systems are also discussed. The clinical implications of the FDA’s decision to remove ETASU C are noted, followed by several actionable recommendations to the FDA. Keywords: induced abortion; medical abortion; medication abortion; induced termination of pregnancy; mifepristone; Risk Evaluation and Mitigation Strategy; Elements to Assure Safe Use; Food and Drug Administration

Zitieren

APA

Sluzala, Z., & Skop, I. (2026). A Critical Analysis of the FDA’s 2021 Mifepristone REMS Modification Rationale Review. Issues in Law & Medicine. https://doi.org/10.70257/wfev6833

Vancouver

Sluzala Z, Skop I. A Critical Analysis of the FDA’s 2021 Mifepristone REMS Modification Rationale Review. Issues in Law & Medicine. 2026. doi:10.70257/wfev6833

BibTeX
@article{Sluzala2026,
  author = {Sluzala, Zachary and Skop, Ingrid},
  title = {A Critical Analysis of the FDA’s 2021 Mifepristone REMS Modification Rationale Review},
  journal = {Issues in Law & Medicine},
  year = {2026},
  doi = {10.70257/wfev6833}
}
Kostenlos starten →